Treatment and endpoints. – AIEOP-BFM ALL – AIEOP-BFM ALL • Perspectives. ALL, acute lymphoblastic leukemia; MRD, minimal residual disease. Principal investigator of clinical trial. Pr Martin SCHRAPPE; Klinik für Kinder- und Jugendmedizin I; Universitätsklinikum Schleswig-Holstein – Campus Kiel. Blood ; doi: .. Accordingly, in the AIEOP-BFM ALL study, these 2 groups of patients.

Author: Mezilrajas Malazragore
Country: Mali
Language: English (Spanish)
Genre: Music
Published (Last): 19 August 2006
Pages: 84
PDF File Size: 4.70 Mb
ePub File Size: 2.41 Mb
ISBN: 166-1-98570-466-2
Downloads: 31074
Price: Free* [*Free Regsitration Required]
Uploader: Gardagor

Pediatr Blood Cancer End of recruitment; Anna Kinderkrebsforschung Full Title: Receiver operating characteristic ROC aol was performed using Medcalc to estimate the best discriminatory thresholds for MRD [15].


Is it possible to improve the outcome and to achieve a further reduction of leukemic cell burden by administration of an innovative treatment schedule 2009 We therefore arbitrarily defined an extra MRD threshold for precursor B-ALL patients at both day 15 and day 33 20009 order to distinguish 3 risk groups with a reasonable number of patients Figure 4C, 4D.

In contrast it was significant for precursor B-ALL patients at both time points.

Please review our privacy policy. It is also important to note that these criteria identified 13 of the 14 precursor B-ALL patients originally stratified as high risk due to high MRD at day Earlier stratification of high risk patients in clinical trials may be beneficial in enabling novel treatments to be trialled on patients who achieve only a shallow remission at the end of induction with reductions in MRD providing a surrogate end-point.

This study was funded by project grants and from the National Health and Medical Research Council www.


Download Options Subscribe to this Search. Parental consent was given for all patients at the hospitals and a copy forwarded to CCIA.

Both Female Only Male Only. These effects were not apparent in the 30 T-ALL patients but were maintained in the whole cohort.

Support Center Support Center. The potential benefit of this alternative patient stratification is clear from a comparison of the original 20009 Figure 5B and the new alternative Figure 5C.

Trials with results Trials without results. Relapse-free survival RFS was defined as time from remission to either relapse or last clinical follow up.

Male, Female Trial protocol: The advanced knowledge about genetics of ALL and molecular regulation of treatment response and zieop-bfm represents the basis for the design of contemporary treatment protocols. High Risk patients as identified by day 33 – randomized study question: The purpose of this study was to further aiwop-bfm stratification by MRD measurement at an earlier stage. How to search [pdf].

Trials shown on current akeop-bfm Selected Trials only. Trial documentation Melanie Gerzmehle Univ. Received Jun 25; Accepted Aug The day 15 MRD analysis was performed retrospectively using the more sensitive or the first marker used for stratification. Identification of a new poor early response group within medium risk for MRD risk stratification.

The value of MRD at even earlier timepoints in induction day 15 or day 19 in the identification of patients with particularly favourable outcomes has already been established for MRD measured by quantitative flow cytometry [6][7] and in small 209 studies [8] — [10]. SR patients identified by at least one sensitive marker: Statistics Relapse-free survival RFS was defined as time from remission to either relapse or last clinical follow up.


Reviewed and contributed to the manuscript and approved final form: In Table 1the characteristics of the whole group of patients are compared with the 89 patients excluded due to lack of day 15 sample or suitable assay; with the patients included and the 53 included patients who relapsed.

Query did not match any studies. Summary Details Full Trial Details. Assessment of optimal thresholds for MRD prediction of relapse.

Clinical Trials Register

EU Clinical Trials Register. Table 1 Characteristics of the patient cohort for this study. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Giles1 Anita Y. Monitoring Tanja Schindelmeiser Univ. Standard risk and medium risk patients were treated uniformly according to the common control arm in BFM ALL and high risk patients were assigned to treatment with novel high risk chemotherapy blocks [4]. These data collectively suggested that the early MRD timepoints can provide additional prognostic information useful for stratifying patients with precursor B-ALL.

Results The Lal results at day 15 and day 33 were first evaluated by comparing the proportion of patients with low, moderate, high and very high levels of MRD in relapsed and non-relapsed patients Figure 2. Progress in the treatment of acute lymphoblastic leukaemia in children and adolescents has been made in the last 10 to15 years mainly through refinement of risk stratification and adaptation of chemotherapy.